On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The plaintiffs ...

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative diseases, such as Alzheimer’s disease (AD), is expected to report ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal ...

Cassava Sciences Price Performance Shares of NASDAQ SAVA opened at $2.42 on Friday. The stock has a market capitalization of $116.43 million, a PE ratio of -1.75 and a beta of -0.95. Cassava ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the ...

As you can see from the chart above the percentage of shares that are sold short for Cassava Sciences has declined since its last report. This does not mean that the stock is going to rise in the near ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.